secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0001438533-25-000020
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere's FILSPARI gets standard EU marketing authorization; receives $17.5M milestone
--------------------------------------------------------------------------------

- European Commission converts conditional approval to standard MA for FILSPARI (sparsentan) for primary IgAN in all EU member states, plus Iceland, Liechtenstein, Norway.
- UK MHRA also converted to standard approval on April 15, 2025.
- Company receives $17.5M milestone payment from CSL Vifor; eligible for additional market access and sales-based milestones.
- Approval based on Phase 3 PROTECT Study showing significant slowing of kidney function decline vs. irbesartan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000020/0001438533-25-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000020/tvtx-20250429.htm
  HTML page:      https://secwatch.observer/filing/0001438533-25-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer